Pulmatrix (NASDAQ:PULM) Now Covered by StockNews.com

Equities researchers at StockNews.com began coverage on shares of Pulmatrix (NASDAQ:PULM) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the biotechnology company’s stock.

Pulmatrix Stock Up 0.3%

Shares of NASDAQ PULM opened at $6.50 on Tuesday. Pulmatrix has a twelve month low of $1.72 and a twelve month high of $10.40. The firm has a market cap of $23.73 million, a PE ratio of -2.46 and a beta of 1.38. The business has a fifty day simple moving average of $6.44 and a two-hundred day simple moving average of $6.44.

Pulmatrix (NASDAQ:PULM) last released its quarterly earnings data on Thursday, May 15th. The biotechnology company reported ($0.50) earnings per share for the quarter. Pulmatrix had a negative net margin of 96.51% and a negative return on equity of 45.97%.

Hedge Funds Weigh In On Pulmatrix

An institutional investor recently raised its position in Pulmatrix stock. Geode Capital Management LLC boosted its stake in shares of Pulmatrix, Inc. (NASDAQ:PULM) by 24.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 36,871 shares of the biotechnology company’s stock after buying an additional 7,290 shares during the period. Geode Capital Management LLC owned 1.01% of Pulmatrix worth $257,000 as of its most recent filing with the Securities & Exchange Commission. 11.84% of the stock is currently owned by institutional investors.

About Pulmatrix

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.